Literature DB >> 33960818

Epidemiology of extended-spectrum β-lactamase and metallo-β-lactamase-producing Escherichia coli in South Asia.

Kamrul Islam1, Aaron J Heffernan1,2, Saiyuri Naicker1, Andrew Henderson3,4, Mohammed Abul Hassan Chowdhury5, Jason A Roberts1,3,6,7, Fekade B Sime1,3.   

Abstract

Aim: To determine the prevalence of extended-spectrum β-lactamase (ESBL) and metallo-β-lactamase (MBL)-producing Escherichia coli in South Asia. Methodology: A systematic review and meta-analysis of data published in PubMed, EMBASE, Web of Science and Scopus.
Results: The pooled prevalence of ESBL and MBL-producing E. coli in South Asia were 33% (95% CI: 27-40%) and 17% (95% CI: 12-24%), respectively. The prevalence of blaCTX-M type was 58% (95% CI: 49-66%) with blaCTX-M-15 being the most prevalent (51%, 95% CI: 40-62%) variant. The most prevalent MBL variant was blaNDM-1 (33%, 95% CI: 20-50%).
Conclusion: This study suggests a high prevalence of ESBLs and MBLs among E. coli clinical isolates. Comprehensive resistance surveillance is required to guide clinicians prescribing antibiotics in South Asia.

Entities:  

Keywords:  Escherichia coli; South Asia; extended-spectrum β-lactamase; meta-analysis; metallo-β-lactamase; prevalence

Mesh:

Substances:

Year:  2021        PMID: 33960818     DOI: 10.2217/fmb-2020-0193

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  2 in total

1.  Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model.

Authors:  Kamrul Islam; Fekade B Sime; Steven C Wallis; Michelle J Bauer; Saiyuri Naicker; Hayoung Won; Hosam M Zowawi; Md Abu Choudhury; Tahmina Shirin; Zakir H Habib; Patrick N A Harris; Meerjady S Flora; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2022-08-04       Impact factor: 5.938

2.  Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.

Authors:  Kamrul Islam; Fekade B Sime; Steven C Wallis; Michelle J Bauer; Brian M Forde; Patrick Harris; Tahmina Shirin; Zakir H Habib; Meerjady S Flora; Jason A Roberts
Journal:  J Antimicrob Chemother       Date:  2022-08-25       Impact factor: 5.758

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.